



**CANNABINOID**  
conference 2017

IACM 9<sup>th</sup> Conference on Cannabinoids in Medicine  
Maritim Hotel Cologne, Germany, 29-30 September 2017

<http://cannabinoidconference2017.org>

## Program

Last update: 05 September 2017

## Friday, September 29

<b>08:00 - 17:00</b>		<b>Registration</b>
		Presentation
09:00 - 09:40	<b>Where do we stand?</b>	<b>Session I: Accepted medical uses and medications</b> <u>Donald Abrams</u> : "Cannabis-based medicines: an introductory overview of all the major clinically relevant known knowns and known unknowns"
09:40 - 10:20		<u>Ryan Vandrey</u> : "Evaluating the impact of cannabis use in the human laboratory and via patient registry surveys"
10:20 - 11:00		<u>Kirsten Müller-Vahl</u> : "Current cannabis-based medicines: a clinician's perspective"
11:00 - 11:15		Break
11:15 - 11:30		<u>Timna Naftali</u> : "The effect of cannabis on Crohn's disease patients"
11:30 - 11:45		<u>Lihi Bar-Lev Schleider</u> : "Epidemiological characteristics, safety and efficacy of medical cannabis use in cancer patients" <u>Aleksi Hupli</u> : "Medical cannabis for ADHD: a medical

11:45 – 12:00		sociological patient case study of cannabinoid therapeutics in Finland”
12:00 – 12:15		<u>Carl Roberts</u> : “Exploring the munchies: investigation of cannabis effects on human appetite and the development of the cannabis eating experience questionnaire”
12:15 – 12:30		<u>Ran Abuhasira</u> : “Epidemiological characteristics, safety and efficacy of medical cannabis in older subjects”
12:30 – 13:00		<u>Questions from a panel of experts</u> : “What information do patients and their clinicians need?”
13:00 – 15:00		Lunch and <b>poster session 1</b>
15:00 – 15:40		<b>Session II: Genetics, strains and quality</b> <u>Ethan Russo</u> : “Chemovars (and a comparison of sativa & indica)”
15:40 – 16:20		<u>Jahan Marcu</u> : “Nature, variability & safety of marketed cannabis (NB pesticides) & how to optimize the safety & medical efficacy of marketed cannabis”
16:20 - 16:35		Break
16:35 – 17:05		<b>Session III: Laws and politics</b> <u>Mark Ware</u> : “Impact of new regulations on medical and recreational cannabis”
17:05 – 17:20		<u>Jeffrey Hergenrather</u> : “Country report: USA”
17:20 – 17:35		<u>Ilija Reznik</u> : “Country report: Israel”
17:35 – 17:50		<u>Franjo Grotenhermen</u> : “Country report: Germany”
17:50 – 18:05		<u>Sébastien Béguerie</u> : “Country report: France”
18:05 – 18:35		<u>Questions from a panel of experts</u> : “What are the best (and worst) ways forward for patients and their clinicians?”
19:00 – 22:00		<b>Dinner of IACM partner organizations and ambassadors</b>



# Saturday, September 30

08:15 - 12:00		<b>Registration</b>
		Presentation
09:00 – 09:40	<b>Where do we go?</b>	<b>Session IV: Emerging new indications</b> <u>Jonathan Page</u> : “Biochemical genomics of cannabis strain diversity”
09:40 – 10:20		<u>Roger Pertwee</u> : “Future exploitation in the clinic of the endocannabinoid system and of synthetic drugs - most promising future directions”
10:20 – 11:00		<u>Guillermo Velasco</u> : “Promising future directions: cannabinoid medicines versus cancer”
11:00 – 11:15		Break
11:15 – 11:30		<u>Yosef Sarne</u> : “Reversal of age-associated cognitive impairments by ultra-low doses of tetrahydrocannabinol”
11:30 – 11:45		<u>Elon Eisenberg</u> : “Cannabis treatment in hospitalized patients, using the syqe -exo inhaler - results of a pilot open-label study”
11:45 – 12:00		<u>Zoltán Balogh</u> : “Endocannabinoid interactions in the regulation of behavioral responses to trauma”
12:00 – 12:15		<u>Jan G. Ramaekers</u> : “Brain kinetics of neurometabolites during cannabis intoxication”
12:15 – 12:55		<u>Daniele Piomelli</u> : “The future of cannabis-based medicines: a pharmacologist's perspective”
12:55 – 15:00		Lunch and <b>poster session 2</b>
15:00 – 15:40		<b>Session V: Knowledge and education</b> <u>Franjo Grotenhermen</u> : “Promising indications with limited clinical evidence”
15:40 – 16:20		<u>Raquel Peyraube</u> : “What questions do clinicians and patients have on a treatment with cannabis-based medicines?”
16:20 – 17:00		<u>Questions from a panel of experts</u> : “What should clinicians, patients and regulators know? What questions are still waiting for an answer?”

17:00 – 17:15		Break
17:15 – 18:30		<b>IACM General Meeting</b>
19:00 – 22:00		<b>Dinner with Award Ceremony</b>

### **Special thanks**

Special thanks by the IACM Board of Directors go to our platin sponsors **Bedrocan** ([www.bedrocan.com](http://www.bedrocan.com)) and **ABcann Germany** for their extraordinary contribution to the conference to allow us to invite the best speakers for every topic and make this program possible.